101ST GENERAL ASSEMBLY
State of Illinois
2019 and 2020
SB2340

 

Introduced 1/8/2020, by Sen. Laura Fine

 

SYNOPSIS AS INTRODUCED:
 
720 ILCS 570/315.6 new

    Amends the Illinois Controlled Substances Act. Provides that a prescriber who is licensed to prescribe controlled substances shall, prior to issuing a prescription for an opioid that is a Schedule II controlled substance, discuss with a patient who is under 18 years of age and is an emancipated minor, or with the patient's parent or guardian if the patient is under 18 years of age and is not an emancipated minor, the risks of developing a physical or psychological dependence on the opioid and, if the prescriber deems it appropriate, any alternative treatments as may be available. Provides that a prescriber who engages in a discussion required under this provision shall include a note in the patient's medical record indicating that the discussion took place. Provides that the discussion required under this provision shall not be required prior to issuing a prescription to any patient who is currently receiving hospice care from a comprehensive hospice licensed under the Hospice Program Licensing Act. Effective immediately.


LRB101 16214 RLC 65586 b

 

 

A BILL FOR

 

SB2340LRB101 16214 RLC 65586 b

1    AN ACT concerning criminal law.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Illinois Controlled Substances Act is
5amended by adding Section 315.6 as follows:
 
6    (720 ILCS 570/315.6 new)
7    Sec. 315.6. Prescriber to discuss risks of dependence on
8opioids with certain patients.
9    (a) In this Section, "opioid" means a narcotic drug or
10substance that is a Schedule II controlled substance under
11paragraph (1), (2), (3), or (5) of subsection (b) or under
12subsection (c) of Section 206 of this Act.
13    (b) A prescriber who is licensed to prescribe controlled
14substances shall, prior to issuing a prescription for an opioid
15that is a Schedule II controlled substance, discuss with a
16patient who is under 18 years of age and is an emancipated
17minor, or with the patient's parent or guardian if the patient
18is under 18 years of age and is not an emancipated minor, the
19risks of developing a physical or psychological dependence on
20the opioid and, if the prescriber deems it appropriate, any
21alternative treatments as may be available.
22    (c) A prescriber who engages in a discussion required under
23subsection (b) shall include a note in the patient's medical

 

 

SB2340- 2 -LRB101 16214 RLC 65586 b

1record indicating that the discussion took place.
2    (d) The discussion required under subsection (b) shall not
3be required prior to issuing a prescription to any patient who
4is currently receiving hospice care from a comprehensive
5hospice licensed under the Hospice Program Licensing Act.
 
6    Section 99. Effective date. This Act takes effect upon
7becoming law.